MEK inhibitors for the treatment of non-small cell lung cancer

Jing Han(University of North Carolina at Chapel Hill), Qiming Wang(Hunan Cancer Hospital), Xuan Wu(Zhengzhou University), Hongle Li(Shanghai Jiao Tong University), Sen Yang, Yang Liu(Zhengzhou University)
Journal of Hematology & Oncology
January 5, 2021
10.1186/s13045-020-01025-7
Cited by 300

Related Papers

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311
Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity
|Cell Death and Disease|2023|130
Roles of exosomes in immunotherapy for solid cancers
|Cell Death and Disease|2024|106